Sector News

Though sales are up, Boston Scientific’s net Q1 profit shrinks to $11M in the face of COVID-19

April 30, 2020
Life sciences

Though its first-quarter sales were up—due in no small part to the closure of its $4.2 billion acquisition of BTG last year—Boston Scientific’s total net income shrank down to a slim margin compared to 2019’s lead-off quarter.

As the novel coronavirus spread across the world over the past months, forcing many hospitals and patients to forgo less urgent medical procedures, Boston Scientific posted a net income of $11 million, or one penny per share, compared to the $424 million it saw last year.

Newly acquired products from BTG—which include a host of peripheral interventions—as well as those from its $465 million deal for spine-spacer developer Vertiflex had a 6.1% positive impact on Boston Scientific’s bottom line.

Reported net sales totaled $2.54 billion, up 2% compared to last year’s $2.49 billion. But without those added products, and minus the impact of foreign currency fluctuations, sales would have been down 2.9%, the company said. Meanwhile, overall operating expenses rose from $1.22 billion to $1.59 billion.

Cardiovascular sales saw 5.5% growth from $972 million to over $1.02 billion, with a boost from BTG’s portfolio of vascular filters, catheters and clot-dissolving systems aimed at treating cancers and pulmonary embolisms. Meanwhile, heart rhythm management and electrophysiology sales dropped 11% and 6.2%, respectively, as surgeries have been postponed.

“During this global pandemic, we are grounded in the urgency of providing important medical products and therapies to those who need them—in particular, many patients with acute needs,” Boston Scientific Chairman and CEO Mike Mahoney said in a statement.

To help address COVID-19, the company worked with the University of Minnesota to develop the Coventor emergency resuscitator as a ventilator alternative and received an FDA authorization in mid-April. It has also been working on reusable personal respirators and the production of face shields.

“We continue to balance short-term adjustments to our plans while strengthening our long-term strategy to serve our customers and deliver high performance,” Mahoney added. “I’m confident in our ability to bring meaningful, innovative products to market, and grateful for our team’s winning spirit as we navigate the impact of these challenges.”

The company’s stock was up 2% following the news. Worldwide, the devicemaker saw a 6.4% decrease in Asia-Pacific sales and a 1.6% decline across Europe, the Middle East and Africa. Sales in a group of 20 countries that Boston Scientific considers to be emerging markets saw a drop of 10.1%.

The company also said it increased its available liquidity to about $2.6 billion, with a new $1.25 billion term loan agreement to refinance its previous borrowings.

As for the remainder of 2020, Boston Scientific said it is unable to estimate the overall impact it will see from COVID-19 and economic slowdowns. Earlier this month, the company cut wages and hours for many of its employees, according to a report from The Boston Globe.

By: Conor Hale

Source: Fierce Biotech

comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach